Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00310258 · ClinicalTrials.gov registry record · Phase 3
Drug Use Prevention Among Girls Through a Mother-Daughter Intervention
A Phase 3 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
NCT00310258 is a Phase 3 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 2,000 participants.
The verdict
NCT00310258, a Phase 3 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
This study will develop and test drug use prevention strategies for low-income, minority girls. Gender-specific substance use rates, risk and protective factors, and health outcomes highlight the need for interventions aimed at girls. Girls and boys share a number of risk factors, yet some factors are more salient for one gender. Girls and boys may also be affected differently by the same risk factors. Intervention planned for this study emphasizes risk and protective factors that impact girls. Our intervention will build mother-daughter communication and closeness; enhance girls' self-efficacy and body esteem; nurture girls' conflict management, problem-solving, stress reduction, and refusal skills; correct perceived norms; build social supports; and establish patterns of parental monitoring and supervision. We hypothesise that girls who receive GSI will have lower 3-year follow-up rates of substance use than girls who receive no intervention. The study will occur in three phases. In a 12-month preparation phase, we will refine and complete intervention and measurement protocols, recruit subjects and randomly assign girls and mothers to study arms, and pretest girls and mothers. A 12-month implementation phase will initiate field operations of the clinical trial, including intervention delivery, process data collection, and posttests. Follow-up in the last 36 months will involve longitudinal measurements of girls and mothers, booster session development and delivery, and data analyses.
Interventions
- BEHAVIORAL Drug use prevention intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00310258
The ClinicalTrials.gov registry entry for NCT00310258 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Drug use prevention intervention is the first listed.
NCT00310258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00310258 about?
NCT00310258 is a clinical study titled "Drug Use Prevention Among Girls Through a Mother-Daughter Intervention". This study will develop and test drug use prevention strategies for low-income, minority girls. Gender-specific substance use rates, risk and protective factors, and health outcomes highlight the need for interventions aimed at girls. Girls and boys share a number of risk factors, yet some factors a...
What is the current status of trial NCT00310258?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2005-04. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00310258?
The interventions under investigation include: Drug use prevention intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT00310258?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.